New drug duo aims to shrink tough cancers
NCT ID NCT06475300
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 570 adults will take part, and the trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug) combined with a PD-1 monoclonal antibody (an immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors.
What could go wrong
This is an early-phase trial (Phase 2) with no results yet. The combination may not work better than existing treatments, and side effects from the drugs could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact